KALA BIO (KALA) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for KALA BIO.

Analyst Coverage

Research analysts who have asked questions during KALA BIO earnings calls.

Andreas Argyrides

Oppenheimer & Co. Inc.

3 questions for KALA

Also covers: AQST, ARSP, CLSD +7 more

François Brisebois

Oppenheimer & Co. Inc.

3 questions for KALA

Also covers: ACHV, AQST, AVDL +11 more

Chris Howerton

Jefferies

2 questions for KALA

Also covers: CLDX, LYRA, PTGX +1 more

Christopher Neyor

JPMorgan Chase & Co.

2 questions for KALA

Yi Chen

H.C. Wainwright & Co.

2 questions for KALA

Also covers: ANGO, APDN, BLFS +22 more

Chris Neyor

JPMorgan Chase & Co.

1 question for KALA

Tim Chiang

Northland Securities, Inc.

1 question for KALA

Also covers: IDYA

Latest news

Recent press releases and 8-K filings for KALA.

Kala Bio Stockholders Approve Proposals at 2025 Annual Meeting

KALA

Proxy Vote Outcomes

Convertible Preferred Issuance

Delisting/Listing Issues

At the 2025 annual meeting held on January 30, 2026, Kala Bio, Inc. stockholders approved the election of Mark Iwicki, Todd Bazemore, and David Lazar as Class II directors.
Stockholders ratified HCL International LLC as the independent registered public accounting firm for fiscal year 2025 and approved the compensation of named executive officers.
Key approvals included increasing the number of authorized common stock from 125 million to 1.5 billion shares and authorizing the issuance of common stock upon conversion of Series AA and Series AAA convertible preferred stock.
The board of directors was also authorized to effect a reverse stock split at any ratio between 1-for-2 and 1-for-100.

5 hours ago

Transcript

Kala Bio Stockholders Approve Key Capital Structure Changes

KALA

Proxy Vote Outcomes

Convertible Preferred Issuance

Delisting/Listing Issues

Kala Bio, Inc. stockholders approved an amendment to increase the number of authorized shares of common stock from 125 million shares to 1.5 billion shares.
Stockholders also authorized the board of directors to effect a reverse stock split of the company's outstanding common stock at any ratio between 1-for-2 and 1-for-100.
The election of Mr. Mark Iwicki, Mr. Todd Bazemore, and Mr. David Lazar as Class II directors was approved, with their terms expiring at the 2028 annual meeting.
The selection of HCL International LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Stockholders authorized the issuance of common stock upon conversion of Series AA and Series AAA convertible preferred stock.

5 hours ago

Transcript

Kala Bio Stockholders Approve Director Elections, Executive Compensation, Increased Authorized Shares, and Reverse Stock Split Authority

KALA

Proxy Vote Outcomes

Board Change

Delisting/Listing Issues

Stockholders elected Class II directors Mark Iwicki, Todd Bazemore, and David Lazar.
The non-binding advisory compensation of named executive officers was approved, and HCL International LLC was ratified as the independent registered public accounting firm for fiscal year 2025.
Shareholders approved an amendment to increase the number of authorized common shares from 125 million to 1.5 billion shares.
The board was authorized to implement a reverse stock split of outstanding common stock at a ratio between 1-for-2 and 1-for-100.
Authorization was also granted for the issuance of common stock upon conversion of Series AA and Series AAA convertible preferred stock.

5 hours ago

Transcript

KALA BIO Enters At-The-Market Offering Agreement

KALA

KALA BIO, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC on January 8, 2026, for the sale and issuance of its common stock.
The agreement allows for the sale of up to $15,000,000 in common stock through Wainwright as a sales agent or principal.
KALA BIO will pay Wainwright a sales commission equal to 3.0% of the gross sales price of the shares sold.
The Company retains the right to designate sales parameters and is not obligated to sell any shares under the agreement.

Jan 8, 2026, 9:07 PM

8-K

KALA BIO Settles Debt and Issues Common Stock

KALA

Legal Proceedings

Executive Compensation

KALA BIO, Inc. successfully settled approximately $10.6 million of debt with Oxford Finance, LLC by making a $2 million payment, fully satisfying and discharging all obligations as of December 26, 2025.
On December 30, 2025, the company issued an aggregate of 4,600,000 shares of common stock in private transactions, including 400,000 shares to new employees and shares to settle obligations with Baker Bros. Advisors LP (900,000 shares), LifeSci Capital LLC (2,200,000 shares), and Delaware IR LLC (1,100,000 shares to settle a $600,000 debt).

Jan 6, 2026, 12:30 PM

8-K

KALA BIO Announces Closing of $10 Million Registered Direct Offering

KALA

KALA BIO, Inc. announced the closing of its previously announced registered direct offering on December 5, 2025.
The offering involved the purchase of an aggregate of 10,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.00 per share.
The aggregate gross proceeds to the company from the offering were approximately $10 million.
KALA BIO intends to use the net proceeds from the offering to repay certain of its indebtedness and for general corporate purposes.

Dec 5, 2025, 9:05 PM

8-K

KALA BIO, Inc. Secures Investment and Appoints New CEO Amidst Financial Restructuring

KALA

CEO Change

Board Change

Convertible Preferred Issuance

KALA BIO, Inc. entered into a Securities Purchase Agreement with David Lazar for a $6.0 million investment. The First Closing of $1.8 million occurred on November 24, 2025, with the Second Closing of $4.2 million expected by March 31, 2026, pending stockholder approval.
David Lazar was appointed Chief Executive Officer and Chairman of the Board following the First Closing, and Mary Reumuth was terminated as Chief Financial Officer.
The company reached a Loan Settlement Agreement with Oxford Finance LLC to settle loan obligations for $2.0 million cash and 1,620,000 shares of Common Stock, with $1.0 million from the Second Closing allocated to Oxford. This settlement follows a period where Oxford had issued a default notice, intended to foreclose on assets, and swept the company's cash resources.

Nov 25, 2025, 9:15 PM

8-K

KALA BIO, Inc. Enters Convertible Loan Agreement for up to $375,000

KALA

Debt Issuance

New Projects/Investments

Profit Warning

KALA BIO, Inc. entered into a Convertible Loan Agreement on November 9, 2025, with an individual investor for up to $375,000 at a 15% annual interest rate.
The loan is scheduled to be funded in two tranches: $187,500 by November 10, 2025, and the remaining $187,500 by November 12, 2025.
The proceeds from this loan are restricted for specific uses: facilitating the negotiation and finalization of an additional investment transaction with the lender and preparing and filing the Q3 2025 Quarterly Report.
The company is facing significant financial challenges, as Oxford Finance LLC previously swept substantially all of its cash resources and intended to foreclose on assets, though foreclosure efforts were paused on November 3, 2025, allowing $125,000 for immediate needs.
KALA BIO plans to explore strategic options and seek additional financing, but if further funding is not secured, Oxford is expected to resume foreclosure on the company's assets.

Nov 10, 2025, 1:00 PM

8-K

KALA BIO receives notice of loan default

KALA

On September 29, 2025, KALA BIO, Inc. received a written notice of event of default from Oxford Finance LLC.
The notice asserted an event of default under Section 8.3 (Material Adverse Change) of the Loan and Security Agreement.
As a result of the default, Oxford Finance LLC declared all obligations of the Company under the Loan Agreement immediately due and payable.
The total amount of the Company's obligations accelerated and declared payable by Oxford is $29.1 million, plus any additional interest and expenses.

Oct 1, 2025, 12:00 PM

8-K

KALA BIO's KPI-012 Phase 2b Trial Fails Primary Endpoint

KALA

Layoffs

Guidance Update

Profit Warning

KALA BIO's CHASE Phase 2b clinical trial for KPI-012 in treating persistent corneal epithelial defect (PCED) did not meet its primary endpoint of complete healing, nor did it achieve statistical significance for secondary endpoints.
Despite KPI-012 being well-tolerated with a favorable safety profile, KALA BIO will cease development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform due to the lack of efficacy.
The company plans to evaluate strategic options, engage with its secured lender, and implement cash preservation measures, including a reduction in workforce.